3113 – FORTY-EIGHT WEEK EFFICACY AND SAFETY OF PEGCETACOPLAN IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND SUBOPTIMAL RESPONSE TO PRIOR ECULIZUMAB TREATMENT

Pegcetacoplan (PEG) is a C3 complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). PEG was superior to eculizumab (ECU; C5-inhibitor) in improving hemoglobin (Hb) levels and clinical outcomes at Week 16 (phase 3 PEGASUS trial NCT03500549). Here, we report efficacy and s...

Full description

Bibliographic Details

Published in:	Experimental hematology Vol. 100; p. S97
Main Authors:	de Latour, Régis Peffault, Szer, Jeffrey, Weitz, Ilene, Röth, Alexander, Höchsmann, Britta, Panse, Jens, Usuki, Kensuke, Griffin, Morag, Kiladjian, Jean-Jacques, de Castro, Carlos, Nishimori, Hisakazu, Tan, Lisa, Al-Adhami, Mohammed, Deschatelets, Pascal, Francois, Cedric, Grossi, Federico, Risitano, Antonio, Hillmen, Peter
Format:	Journal Article
Language:	English
Published:	Elsevier Inc 01.08.2021
Subjects:	Advanced Basic Science Hematology, Oncology, and Palliative Medicine
ISSN:	0301-472X, 1873-2399
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!